Onco Actu du 9 avril 2015

Sommaire 1. Biologie Researchers identify subtype of lethal prostate cancer [SUNY Upstate Medical University] Biologists identify brain tumor weakness [MIT News] 2.5 Etiologie - Gènes For cancer risk, some BRCA mutations are more dangerous than others [LA Times] 2.8 Etiologie - Contraceptifs, THS No strong association between lung cancer risk in women and reproductive history or hormone use [IASLC] 3.1 Tabac U.S. appeals court deals setback to Florida tobacco plaintiffs [Reuters] 4.9 Dép., diag. & prono. - Sein Breast cancer risk test devised in 77-gene analysis [BBC News] Genetic screening could improve breast cancer prevention [The Institute of Cancer Research] 5. Traitements Cancer treatment gets more personalised than ever [PHG Foundation] Doctors Test Tumor Paint In People [NPR] Too Many Favorable Clinical Trials? Maybe Not [In the Pipeline] 5.2 Pharma A CEO's View On Cancer, Virus-Based 'Cures,' And '60 Minutes' Vs. Reality [Forbes] UK biotech Silence Therapeutics raises $58 million for its RNA drive [Reuters] 5.2.1 Pharma - Partenariats Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for the Treatment of Advanced Prostate Cancer [Merck] 5.3 Traitements - FDA, EMA,... Promoting high quality scientific research in paediatric medicines [EMA] 5.4 Traitements - Economie Price of cancer drugs varies widely based on who’s paying [UNC News] 6.6 Publications ORCID Receives a $3 Million Grant to Build International Engagement Capacity [ORCID] 6.8 Communication Film Succeeds in Relaying the Complexity and Hope of Cancer Treatment [CANCER RESEARCH Catalyst]

Les étoiles de couleur jaune signalent des articles dont la lecture est en priorité suggérée (1*) ou recommandée (3*). 1. Biologie Researchers identify subtype of lethal prostate cancer [SUNY Upstate Medical University] “We observed that prostate cancer tumors contain a frequent deletion of the WAVE 1 gene. What’s important, though, is that this WAVE1 gene deletion occurs in metastatic and lethal cancer, thus suggesting that, the WAVE1 gene loss may represent an aggressive subtype of prostate cancer which is more challenging to treat and more likely to progress.” Biologists identify brain tumor weakness [MIT News] The finding also raises the possibility that these GLDC-dependent cells could be killed with drugs that block GLDC activity, according to the researchers, who are now seeking potential drug compounds that could do just that. 2.5 Etiologie - Gènes For cancer risk, some BRCA mutations are more dangerous than others [LA Times] “This study is the first step in defining differences in risk associated with location and type of BRCA1 and BRCA2 mutations.” 2.8 Etiologie - Contraceptifs, THS No strong association between lung cancer risk in women and reproductive history or hormone use [IASLC] Reproductive history, oral contraceptive use, and hormone therapy replacement was evaluated in the 160,855 women eligible to be included in the analysis. Incident lung cancer was observed in 2,467 and the median follow-up was 14 years. 3.1 Tabac U.S. appeals court deals setback to Florida tobacco plaintiffs [Reuters] Tobacco companies said in February that they will pay $100 million to settle most federal smoking lawsuits. Thousands of cases remain pending in state court. 4.9 Dép., diag. & prono. - Sein Breast cancer risk test devised in 77-gene analysis [BBC News] The ability to accurately predict the risk of breast cancer could have a powerful impact on medicine. It could clearly show which women need drugs, such as tamoxifen and raloxifene, to reduce the risk of breast cancer. The lowest-risk women may not need breast cancer screening, while those at highest risk might need to start earlier. Genetic screening could improve breast cancer prevention [The Institute of Cancer Research] Our study is the most definitive so far to show the clear benefits of using genetic testing for a large number of genetic risk factors in identifying women at elevated risk of developing breast cancer. 5. Traitements Cancer treatment gets more personalised than ever [PHG Foundation] The researchers used computational analysis to predict unique neoantigens from the tumour genomic information and select those likely to be the best targets for vaccine. The approach was said to be ‘more like a sniper than a bomb’ – using the neoantigens as flags to specifically target the cancer cells. Doctors Test Tumor Paint In People [NPR] A promising technique for making brain tumors glow so they'll be easier for surgeons to remove is now being tested in cancer patients. Too Many Favorable Clinical Trials? Maybe Not [In the Pipeline] So perhaps these results aren't so much evidence of systematic bias, but evidence that drug research is working the way that it's supposed to. 5.2 Pharma A CEO's View On Cancer, Virus-Based 'Cures,' And '60 Minutes' Vs. Reality [Forbes] Even the Duke treatment that got such high-profile 60 Minutes treatment is not a sure bet for success: Half the patients in the initial trial did not survive, a fact that was glossed over during the report. Thompson believes that understanding the patients who don’t respond to virus-based treatments will be as important as celebrating those who do. UK biotech Silence Therapeutics raises $58 million for its RNA drive [Reuters] Shares in Silence, which reported positive results from Phase II trial of a drug candidate in pancreatic cancer last month, were trading at 260 pence at 0958 EDT, down 1.5 percent. 5.2.1 Pharma - Partenariats Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination with Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for the Treatment of Advanced Prostate Cancer [Merck] ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination. 5.3 Traitements - FDA, EMA,... Promoting high quality scientific research in paediatric medicines [EMA] Registration now open for a workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) on 28 May 2015. 5.4 Traitements - Economie Price of cancer drugs varies widely based on who’s paying [UNC News] Uninsured cancer patients are paying anywhere from two to 43 times what Medicare would pay for chemotherapy drugs, according to a new study from the University of North Carolina at Chapel Hill. 6.6 Publications ORCID Receives a $3 Million Grant to Build International Engagement Capacity [ORCID] Through this engagement with the community of researchers and institutions, ORCID will develop localized technical support infrastructure and materials to support the implementation of persistent identifiers in research workflows. 6.8 Communication Film Succeeds in Relaying the Complexity and Hope of Cancer Treatment [CANCER RESEARCH Catalyst] For those who have been through a cancer diagnosis and treatment, the honesty of behind-closed-door conversations between oncologists and patients facing difficult decisions was striking.